Literature DB >> 10610729

ADAM-TS8, a novel metalloprotease of the ADAM-TS family located on mouse chromosome 9 and human chromosome 11.

K E Georgiadis1, S Hirohata, M F Seldin, S S Apte.   

Abstract

A disintegrin-like and metalloprotease domain with thrombospondin type I modules (ADAM-TS) describes a novel family of zinc metalloendopeptidases. Its members have a common domain organization, which includes, typically, a pre-pro-metalloprotease domain, a disintegrin-like domain, and one or more thrombospondin-like (TS) modules. We describe here the complete primary structure of mouse ADAM-TS8, through cloning of Adamts8 cDNA. This novel member of the family contains two TS modules and is highly similar in sequence and domain organization to three other recently described gene products, ADAM-TS5, ADAM-TS6, and ADAM-TS7. Adamts8 is expressed at low levels throughout development and in adult mouse lung and heart. Through analysis of an interspecific backcross panel, we place the Adamts8 locus on mouse chromosome 9 at a consensus position of 11 cM and its human ortholog, recently reported as the METH2 gene, on human chromosome 11q25. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10610729     DOI: 10.1006/geno.1999.6014

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  11 in total

1.  Identification of a thrombin cleavage site and a short form of ADAMTS-18.

Authors:  Jianhui Wang; Wei Zhang; Zanhua Yi; Shiyang Wang; Zongdong Li
Journal:  Biochem Biophys Res Commun       Date:  2012-02-23       Impact factor: 3.575

2.  Transgenic mice with inactive alleles for procollagen N-proteinase (ADAMTS-2) develop fragile skin and male sterility.

Authors:  S W Li; M Arita; A Fertala; Y Bao; G C Kopen; T K Långsjö; M M Hyttinen; H J Helminen; D J Prockop
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

3.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

4.  The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.

Authors:  Brigette B Y Ma; Fion Sung; Qian Tao; Fan Fong Poon; Vivian W Lui; Winnie Yeo; Stephen L Chan; Anthony T C Chan
Journal:  Invest New Drugs       Date:  2009-01-27       Impact factor: 3.850

5.  C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral stroke.

Authors:  Zongdong Li; Michael A Nardi; Yong-Sheng Li; Wei Zhang; Ruimin Pan; Suying Dang; Herman Yee; David Quartermain; Saran Jonas; Simon Karpatkin
Journal:  Blood       Date:  2009-02-13       Impact factor: 22.113

6.  BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion.

Authors:  Mariano Sebastian Viapiano; Susan Hockfield; Russell Thomas Matthews
Journal:  J Neurooncol       Date:  2008-04-09       Impact factor: 4.130

7.  METH-2 silencing and promoter hypermethylation in NSCLC.

Authors:  J R Dunn; D Panutsopulos; M W Shaw; J Heighway; R Dormer; E N Salmo; S G Watson; J K Field; T Liloglou
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

Review 8.  ADAMTS-18: a metalloproteinase with multiple functions.

Authors:  Jianlu Wei; Chuan-ju Liu; Zongdong Li
Journal:  Front Biosci (Landmark Ed)       Date:  2014-06-01

9.  Emerging Roles of ADAMTSs in Angiogenesis and Cancer.

Authors:  Saran Kumar; Nithya Rao; Ruowen Ge
Journal:  Cancers (Basel)       Date:  2012-11-29       Impact factor: 6.639

10.  Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer.

Authors:  Sergio Alonso; Beatriz González; Tatiana Ruiz-Larroya; Mercedes Durán Domínguez; Takaharu Kato; Akihiro Matsunaga; Koichi Suzuki; Alex Y Strongin; Pepita Gimènez-Bonafé; Manuel Perucho
Journal:  Clin Epigenetics       Date:  2015-12-02       Impact factor: 6.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.